Clinical trial NCT03907540 - References

Autoimmune Diseases — Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025

Citation(s)

•   Schueller O, Skucas E, Regev G, Shaw I, Singh N, Sanghvi M, Croft M, Lohmer L, Alabanza A, Patel J
  Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [(14) C]-Belumosudil in Healthy Men: A Phase 1, Open-Label, 2-Part Study. Clin Pharmacol Drug Dev. 2022 Mar 1. doi: 10.1002/cpdd.1085. [Epub ahead of print]

Open-label, 2-part Study Designated to Assess the Absolute Bioavailability of KD025 and to Determine the Mass Balance Recovery, Metabolite Profile and Identification of Metabolite Structures for [14C]-KD025 in Healthy Male Subjects

Details for clinical trial NCT03907540